Monitor for additional selling in the coming weeks, isolated transactions of this size are routine, but continued outflows could signal caution. Tax-related share surrenders are standard with RSU vesting and not a negative signal.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $482.92entry
- T+1 · 9mo ago −0.58%α −0.03% · $480.12
- T+5 · 9mo ago −1.32%α −0.22% · $476.54
- T+20 · 8mo ago −5.79%α −0.55% · $454.96
- T+60 · 6mo ago −10.87%α −17.82% · $430.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two executives at Vertex Pharmaceuticals executed open-market share sales totaling $433K, while the same insiders also surrendered shares for tax withholding purposes related to equity compensation. The open-market sales are modest in value relative to the company's $122.5B market cap.
Key Financial Metrics
Key Facts
- EVP Edward Atkinson sold 668 shares for $324,881.80 in an open-market transaction.
- SVP Kristen Ambrose sold 223 shares for $108,456.05 in an open-market transaction.
- Both executives also surrendered shares to cover tax liabilities from equity vesting: Atkinson (1,627 shares, $789,273.97) and Ambrose (546 shares, $264,870.06).
- Total open-market proceeds: $433,337.85; total tax-related share surrenders: ~$1.05M.
- All transactions occurred between February 24–25, 2026.
Financial Impact
$433K in net open-market selling by two executives; $1.05M in non-cash tax withholding transactions
Risk Factors
- Perception of insider selling may weigh on sentiment if misinterpreted
- Concentration of selling among C-suite executives, though small in dollar terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-VRTX-1772146834885 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers